GALT Galectin Therapeutics

Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders

Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders

NORCROSS, Ga., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately following the business portion of its 2022 Annual Meeting of Stockholders to be held on Thursday, December 1, 2022 beginning at 11:00 a.m. ET.   

The Annual Meeting of Stockholders and webcast can be accessed via .

Please log in approximately 10 minutes before the event to ensure a timely connection.

About Galectin Therapeutics

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin (formerly known as GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration for NASH with advanced fibrosis. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of combination immunotherapy for advanced melanoma and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at .

Contact

Jack Callicutt, Chief Financial Officer

(678) 620-3186





EN
29/11/2022

Underlying

GALTGalectin Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Galectin Therapeutics

 PRESS RELEASE
Free
GALT Galectin Therap...

Galectin Therapeutics Reports 2025 Financial Results and Provides Busi...

Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “We are at an important juncture for the belapectin development program. During 2025, we made meaningful progress advancing the belapectin program and continuing our analysis of the NAVIGATE ...

March 31, 2026 1 EN
 PRESS RELEASE
Free
GALT Galectin Therap...

Galectin Therapeutics Strengthens Board of Directors with Appointment ...

Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. NORCROSS, Ga., March 17, 2026 (GLOBE NEWSWIRE) --  (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced it has appointed Henry Brem, M.D., as an independent director to its Board of Directors. Dr. Brem is an internationally recognized neurosurgeon-scientist and leader in translational medicine. He serves as the Henry Brem Professor of Neurosurgery at Johns Hopkins University and previously served as Directo...

March 17, 2026 1 EN
 PRESS RELEASE
Free
GALT Galectin Therap...

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin ...

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, March 10, 2026 at 12:00 PM ET. To register, The event will focus on ...

February 26, 2026 1 EN
Free Trial
GALT Galectin Therap...

Galectin Therapeutics Inc: 3 directors

Three Directors at Galectin Therapeutics Inc sold after exercising options/sold 51,770 shares at between 7.038USD and 7.056USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades ...

GALT GALECTIN THERAPEUTICS
12/19/25 December 19, 2025 1 EN
 PRESS RELEASE
Free
GALT Galectin Therap...

Galectin Therapeutics Provides Regulatory Update Following FDA Written...

Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) --  (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that the U.S. Food and Drug Administration (FDA) has provided a written response, and subsequent communications, to the Company’s previously submitted Type C meeting request rega...

December 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch